

## LIDDS moves the publication of the Interim Report for the first quarter 2024

**The board of LIDDS AB (publ) has decided to move forward the publication of the Interim report for the first quarter 2024 to the 30 May.**

Previous date for publication of the Interim report was 27 May 2024. The move is made primarily to be able to present more comprehensible information about the new group.

**For additional information, please contact**

---

Jenni Björnulfson, CEO and CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

### **LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. The company is listed on Nasdaq First North Growth market.

### **Attachments**

---

**LIDDS moves the publication of the Interim Report for the first quarter 2024**